These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7493297)

  • 1. Clinical efficacy of intramuscular human interferon-beta vs interferon-alpha 2b for the treatment of chronic hepatitis C.
    Pérez R; Pravia R; Artímez ML; Giganto F; Rodríguez M; Lombraña JL; Rodrigo L
    J Viral Hepat; 1995; 2(2):103-6. PubMed ID: 7493297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete response to twice-a-day interferon-beta with standard interferon-alpha therapy in acute hepatitis C after a needle-stick.
    Oketani M; Higashi T; Yamasaki N; Shinmyozu K; Osame M; Arima T
    J Clin Gastroenterol; 1999 Jan; 28(1):49-51. PubMed ID: 9916668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial.
    Saracco G; Borghesio E; Mesina P; Solinas A; Spezia C; Macor F; Gallo V; Chiandussi L; Donada C; Donadon V; Spirito F; Mangia A; Andriulli A; Verme G; Rizzetto M
    J Hepatol; 1997 Jul; 27(1):56-62. PubMed ID: 9252074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose increase augments response rate to interferon-alpha in chronic hepatitis C.
    Ferenci P; Stauber R; Propst A; Fiedler R; Müller C; Gschwantler M; Schütze K; Datz C; Judmaier G; Vogel W; Krejs GJ; Gangl A
    Dig Dis Sci; 1996 Dec; 41(12 Suppl):103S-108S. PubMed ID: 9011466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up evaluation in HCV chronic hepatitis treated with alpha-2b interferon. A comparison of two protocols.
    Budillon G; Cimino L; Del Vecchio Blanco C; Mazzacca G; Iaquinto G; D'Ascoli B; Lampasi F; Di Sapio M; Mattera D; Sapio D [corrected to Di Sapio M]
    Ital J Gastroenterol; 1994; 26(1):16-20. PubMed ID: 8025301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus. A prospective, double-blind, randomized study.
    Villa E; Trande P; Grottola A; Buttafoco P; Rebecchi AM; Stroffolini T; Callea F; Merighi A; Camellini L; Zoboli P; Cosenza R; Miglioli L; Loria P; Iori R; Carulli N; Manenti F
    Dig Dis Sci; 1996 Jun; 41(6):1241-7. PubMed ID: 8654159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection.
    Yao GB; Fu XX; Tian GS; Xu DZ; Hao LJ; Huangfu YS; Su CX
    J Gastroenterol Hepatol; 2000 Oct; 15(10):1165-70. PubMed ID: 11106097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study.
    Iino S; Hino K; Kuroki T; Suzuki H; Yamamoto S
    Dig Dis Sci; 1993 Apr; 38(4):612-8. PubMed ID: 8384980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC; Bacon BR; Goldin RD
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group.
    Keeffe EB; Hollinger FB
    Hepatology; 1997 Sep; 26(3 Suppl 1):101S-107S. PubMed ID: 9305673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential interferon-alpha and beta treatment in patients with chronic hepatitis C.
    Miyajima I; Sata M; Uchimura Y; Ide T; Suzuki H; Tanikawa K
    Kansenshogaku Zasshi; 1996 Jul; 70(7):690-5. PubMed ID: 8797303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of interferon alpha-2b and lamivudine combination treatment in comparison to interferon alpha-2b alone in chronic delta hepatitis: a randomized trial.
    Canbakan B; Senturk H; Tabak F; Akdogan M; Tahan V; Mert A; Sut N; Ozaras R; Midilli K; Ozbay G
    J Gastroenterol Hepatol; 2006 Apr; 21(4):657-63. PubMed ID: 16677149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and side effects of intermittent recombinant interferon-alpha 2a in chronic aggressive hepatitis C: with or without initial daily administration.
    Itoh H; Nakata H; Yokoya Y; Nakashima S; Yamanishi T; Hara T; Kawai J; Miyamoto H; Higashi K; Nishioka S
    J Gastroenterol Hepatol; 1996 Aug; 11(8):718-23. PubMed ID: 8872767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of combination therapy of interferon-alpha with ursodeoxycholic acid in chronic hepatitis C: a randomized controlled clinical trial.
    Kiso S; Kawata S; Tamura S; Imai Y; Inui Y; Nagase T; Maeda Y; Yamasaki E; Tsushima H; Igura T; Himeno S; Seki K; Matsuzawa Y
    J Gastroenterol; 1997 Feb; 32(1):56-62. PubMed ID: 9058296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy of interferon-alpha and ursodeoxycholic acid in treatment of chronic type C hepatitis.
    Senturk H; Uzunalimoglu O; Batur Y; Simsek I; Mert A; Ozbay G; Cetinkaya H; Ersoz G; Tabak F; Akbaylar H; Akdogan M; Dokmeci A; Sonsuz A; Ozenirler S; Erden E; Tozum N
    Dig Dis Sci; 1997 Jul; 42(7):1438-44. PubMed ID: 9246043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term titrated recombinant interferon-alpha 2a in chronic hepatitis C: a randomized controlled trial.
    Rumi MG; del Ninno E; Parravicini ML; Romeo R; Soffredini R; Donato MF; Zahm F; Colombo M
    J Viral Hepat; 1995; 2(2):73-6. PubMed ID: 7493300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A preliminary study of retreatment of chronic hepatitis C with interferon.
    Kishihara Y; Hayashi J; Ohmiya M; Nakashima K; Ikematsu H; Kashiwagi S
    Fukuoka Igaku Zasshi; 1995 Apr; 86(4):113-20. PubMed ID: 7782023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group.
    Lindsay KL; Davis GL; Schiff ER; Bodenheimer HC; Balart LA; Dienstag JL; Perrillo RP; Tamburro CH; Goff JS; Everson GT; Silva M; Katkov WN; Goodman Z; Lau JY; Maertens G; Gogate J; Sanghvi B; Albrecht J
    Hepatology; 1996 Nov; 24(5):1034-40. PubMed ID: 8903371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two years versus six months of interferon therapy for chronic hepatitis C.
    Farrell GC
    Dig Dis Sci; 1996 Dec; 41(12 Suppl):93S-98S. PubMed ID: 9011483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients.
    Brouwer JT; Nevens F; Kleter B; Elewaut A; Adler M; Brenard R; Chamuleau RA; Michielsen PP; Pirotte J; Hautekeete ML; Weber J; Bourgeois N; Hansen BE; Bronkhorst CM; ten Kate FJ; Heijtink RA; Fevery J; Schalm SW
    J Hepatol; 1998 Jun; 28(6):951-9. PubMed ID: 9672169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.